Related Experiment Video

Updated: Jun 3, 2026

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

Epidemiology of sudden cardiac death in patients with heart failure

Mahmoud Houmsse1, Veronica Franco, William T Abraham

  • 1Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University Medical Center, Suite 200, 473 West 12th Avenue, Columbus, OH 43210, USA. Mahmoud.houmsse@osumc.edu

Heart Failure Clinics
|March 29, 2011
PubMed

Insights

Congestive heart failure (CHF) mortality stems from pump failure or sudden cardiac death (SCD). Medical therapies targeting neurohormonal changes can prevent SCD in CHF patients, but effectiveness varies by treatment type.

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • Mortality in congestive heart failure (CHF) is often due to progressive cardiac pump failure or sudden cardiac death (SCD).
  • Medical interventions targeting neurohormonal pathways show promise in managing CHF progression and preventing SCD.

Purpose of the Study:

  • To discuss the incidence, prediction, and prevention strategies for sudden cardiac death (SCD) in patients with congestive heart failure (CHF).
  • To review the variable benefits of medical therapies in preventing SCD, depending on the specific treatment used.

Main Methods:

  • Literature review and synthesis of existing research on SCD in CHF.
  • Analysis of medical interventions aimed at counteracting neurohormonal changes.

Main Results:

  • Medical therapies can slow CHF progression and reduce SCD risk.
  • The efficacy of medical therapy for SCD prevention in CHF is inconsistent and depends on the therapeutic agent.

Conclusions:

  • Sudden cardiac death (SCD) remains a significant concern in congestive heart failure (CHF).
  • Understanding the incidence, prediction, and tailored prevention strategies for SCD in both ischemic and nonischemic cardiomyopathy is crucial for improving patient outcomes.

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...